BeOne's GPC3 Bispecific Hits 36% ORR in Liver Cancer; Registrational Trials Planned by Year-End
ONC sits 49% above its 52-week low of $253.948.
Summary
BeOne rolled out a broad slate of solid-tumor data at ESMO 2026, and the lead asset looks credible. Its GPC3×4-1BB bispecific BGB-B2033 posted a 36.0% confirmed response rate at the 450 mg Phase 3 dose in heavily pretreated hepatocellular carcinoma — patients who had mostly already failed PD-(L)1 therapy — versus roughly 5% for TKIs in late-line HCC, with Grade 3+ treatment-related events in just 5.3% of patients. Management plans to start global registrational trials in late-line HCC by the end of 2026, which is the clearest near-term milestone. Early lung cancer data also read well: the brain-penetrant PRMT5 inhibitor BGB-58067 showed a 25.3% confirmed ORR in MTAP-deficient NSCLC (38.5% in EGFR wild-type) and 30.8% intracranial responses, while the CEA ADC BG-C477 hit 56.0% confirmed ORR in CEA-high NSCLC. These are Phase 1 signals, not approvals, and the solid tumor franchise is still years from contributing revenue next to BRUKINSA's $1.2 billion quarterly run rate, but the data support the pipeline story and the planned 2027 late-stage push for the two lung programs.
At the time of this announcement, ONC was trading at $377.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.1B. The 52-week trading range was $253.95 to $388.66. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.